TY - JOUR T1 - Genome-wide association study of problematic opioid prescription use in 132,113 23andMe research participants of European ancestry JF - medRxiv DO - 10.1101/2021.06.03.21258260 SP - 2021.06.03.21258260 AU - Sandra Sanchez-Roige AU - Pierre Fontanillas AU - Mariela V Jennings AU - Sevim Bianchi AU - Yuye Huang AU - Alex Hatoum AU - Julia Sealock AU - Lea K Davis AU - Sarah L Elson AU - 23andMe Research Team AU - Abraham A Palmer Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/26/2021.06.03.21258260.abstract N2 - The growing prevalence of opioid use disorder (OUD) constitutes an urgent health crisis. Ample evidence indicates that risk for OUD is heritable. As a surrogate (or proxy) for OUD, we explored the genetic basis of using prescription opioids ‘not as prescribed’. We hypothesized that misuse of opiates might be a heritable risk factor for OUD. To test this hypothesis, we performed a genome-wide association study (GWAS) of problematic opioid use (POU) in 23andMe research participants of European ancestry (N=132,113; 21% cases). We identified two genome-wide significant loci (rs3791033, an intronic variant of KDM4A; rs640561, an intergenic variant near LRRIQ3). POU showed a positive genetic correlation with the largest available GWAS of opioid dependence and OUD (rg=0.64-0.80). We also identified numerous additional genetic correlations with POU, including alcohol dependence (rg=0.74), smoking initiation (rg=0.63), pain relief medication intake (rg=0.49), major depressive disorder (rg=0.44), chronic pain (rg=0.42), insomnia (rg=0.39), and loneliness (rg=0.28). Although POU was positively genetically correlated with risk-taking (rg=0.38), conditioning POU on risk-taking did not substantially alter the magnitude or direction of these genetic correlations, suggesting that POU does not simply reflect a genetic tendency towards risky behavior. Lastly, we performed phenome- and lab-wide association analyses, which uncovered additional phenotypes that were associated with POU, including respiratory failure, insomnia, ischemic heart disease, and metabolic and blood-related biomarkers. We conclude that opioid misuse can be measured in population-based cohorts and provides a cost-effective complementary strategy for understanding the genetic basis of OUD.Competing Interest StatementPF and SLE are employees of 23andMe, Inc., and hold stock or stock options in 23andMe. The other authors report no conflict of interest.Funding StatementMVJ, YH, SSR and AAP were supported by funds from the California Tobacco-Related Disease Research Program (TRDRP; Grant Number 28IR-0070 and T29KT0526). SB was supported by P50DA037844.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participants provided informed consent and participated in the research online, under a protocol approved by the external AAHRPP-accredited IRB, Ethical & Independent Review Services (http://www.eandireview.com ). The project was approved by the VUMC Institutional Review Board (IRB #160302, #172020, #190418).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe have provided summary statistics for the top 10,000 SNPs (Supplementary Table 24). Full GWAS summary statistics will be made available through 23andMe to qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participants. Interested investigators should email dataset-request{at}23andme.com and reference this paper for more information. ER -